Hints and tips:
...Evan Seigerman, an analyst at BMO Capital Markets, said investors who drove up these stocks in a “sugar-high rush” were now “mentally over the pandemic”....
...Evan Seigerman, analyst at BMO Capital Markets, said the acquisition was a good fit for Pfizer and provided potential cost synergies....
...Evan Seigerman, analyst at BMO Capital markets, said Pfizer management was executing its strategy with transformative business development, pipeline progress and near-term launches....
...“We see no FTC concerns, as Pfizer does not have an antibody-drug conjugate or even a major antibody-based oncology platform,” said Evan Seigerman, analyst at BMO Capital Markets....
...“The market remains nonplussed with Pfizer’s post-Covid story and limited business development in 2022,” said Evan Seigerman, analyst at BMO Capital Markets....
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...“This new class of medicines essentially regulate the hunger-satiety cycle of people and enable doctors to treat obesity like a medical condition,” said Evan Seigerman, an analyst at BMO Capital Markets....
...Evan Seigerman, analyst at BMO Capital Markets, said even though sales of its Covid vaccine — sold under the brand name Comirnaty — had beaten expectations, the company faced challenges next year and would...
...Additional reporting by Judith Evans in London...
...Haleon was created with consumer health assets from GSK, Pfizer and Novartis....
...Evan Seigerman, analyst at BMO Capital Markets, said $5bn was a relatively small deal for Pfizer and that it retains significant capacity to do further acquisitions....
...GlaxoSmithKline and Pfizer are holding out for an improved bid of at least £60bn for their consumer healthcare joint venture, bolstered by shareholder opposition to Unilever’s £50bn offer....
...positive for Bristol, not significantly needle-moving, but [it] adds to the company’s oncology franchise, with a potential approval of the company’s lead asset Repotrectinib in the second half of 2023,” said Evan...
...Unilever said earlier on Saturday that it had “approached GSK and Pfizer about a potential acquisition of the business”....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...J&J is following many other large pharmaceutical companies that have shed their consumer divisions, including GSK and Pfizer, which formed a joint venture from their consumer health units that they plan...
...A year later GSK and Pfizer formed a joint venture from their consumer products divisions, which they plan to spin off next year....
...There was a March release date given for Gran Turismo 7 and the unfortunate slippage of Grand Theft Auto V from November to March. Axios has more....
...Stephen Evans, a professor in pharmacoepidemiology, said it was important to understand “vaccines are not like drugs”....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...“This is good news, mainly because it is not bad news,” said Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine....
...Prof Evans added that data from the BioNTech/Pfizer trial showed that 0.5 per cent of participants who received the placebo had experienced an allergic reaction compared with 0.6 per cent of those who received...
...Three weeks after receiving a first dose of the BioNTech/Pfizer vaccine, sufficient antibody levels to combat the virus were detected in 39 per cent of patients with organ cancer and 13 per cent of those...
...Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said the UK, which has chosen to space the first and second doses of the BioNTech/Pfizer shot beyond...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
International Edition